Psilocybin mushrooms outside the program

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Open-label trial; Also: standard practice.
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: psilocybin-non-program · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

OL · Pr

Tolerance to psilocybin builds within days of repeated use and crosses to LSD, so recent use, including microdosing, can blunt the session dose. Wild or street mushrooms vary in potency and may be misidentified toxic species.

Human data with psilocybin: Human studies with psilocybin

Evidence types on this record

OLOpen-label trial

PrStandard practice; no psilocybin-specific data

02 Pharmacology relevant to psilocybin

None listed

No pharmacology properties of concern are listed for this record.

03 State rules

Official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Isbell H, Wolbach AB, Wikler A, Miner EJ. Cross tolerance between LSD and psilocybin. Psychopharmacologia 1961;2:147–159. — tolerance to psilocybin after repeated daily doses; cross-tolerance with LSD
National Institute on Drug Abuse (NIDA), NIH. Research-topic pages (per-entry link). — people may quickly develop tolerance to psychedelic drugs
National Institute on Drug Abuse (NIDA), NIH. Research-topic pages (per-entry link). — potency varies; misidentification risk

Report an error in this record →